Why Bicara Therapeutics Inc.’s (BCAX) Stock Is Down 9.97%
As of Friday, October 30, Bicara Therapeutics Inc.’s BCAX share price has dipped by 9.97%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Commentary & Analysis
Why Bicara Therapeutics Inc.’s (BCAX) Stock Is Down 15.73%
As of Wednesday, October 28, Bicara Therapeutics Inc.’s BCAX share price has dipped by 15.73%, which has investors questioning if this is right time to buy.Tudor Pop
Why Bicara Therapeutics Inc.’s (BCAX) Stock Is Up 5.67%
As of Tuesday, October 20, Bicara Therapeutics Inc.’s BCAX share price has surged by 5.67%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Bicara Therapeutics Inc.’s (BCAX) Stock Is Down 5.15%
As of Thursday, September 24, Bicara Therapeutics Inc.’s BCAX share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Bicara Therapeutics Inc.’s (BCAX) Stock Is Down 5.40%
As of Wednesday, September 23, Bicara Therapeutics Inc.’s BCAX share price has dipped by 5.40%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | BCAX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $643.9 | $241.2 | 40% |
|
| Shares Out (Mil) | 67.9 | 53.4 | 55% |
|
| Institutional Ownership | 97.4% | 92.9% | 73% |
|
| Float (Mil) | 36.9 | 41.2 | 40% |
|
| Beta | -0.82 | 0.96 | 1% |
|
| Avg Daily Volume (000s) | 2,462 | 486 | 85% |
|
| Price Change (52-week) |
(43.1%) | 48.4% | 23% |
|
| Growth | BCAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 11 | |
| Current EPS | ($0.822) | ($3.386) | ($3.522) | |
| Month Ago EPS | ($0.821) | ($3.381) | ($3.469) | |
| # Rev Up | 0 | 2 | 2 | |
| # Rev Down | 1 | 2 | 0 | |
| Three Months Ago EPS | ($0.848) | ($3.478) | ($3.633) | |
| Year/Year Chg | 0.7% | 34.2% | 25.6% | |
| Financials | BCAX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($185) | ($44) | 7% |
|
| EPS (TTM) | ($3.110) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($135) | ($33) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($340) | $3 | 7% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $960 | $177 | 40% |
|
| Valuation | BCAX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.37 | 2.25 | 38% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | BCAX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (38.4%) | (47.3%) | 14% |
|
| ROE | (41.0%) | (53.3%) | 17% |
|
| Liabilities to Assets | 8.5% | 29.7% | 5% |
|
| F-Score | 2 | 2 | 7% |
|
Bicara Therapeutics Inc. did not pass any screens on 10/29/2026.
